A phase I/II study of LentiGlobin (HPV569) in patients with beta-thalassaemia major or sickle cell anaemia

Trial Profile

A phase I/II study of LentiGlobin (HPV569) in patients with beta-thalassaemia major or sickle cell anaemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2014

At a glance

  • Drugs BB305 beta-globin gene therapy bluebird bio (Primary)
  • Indications Beta-thalassaemia; Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors bluebird bio
  • Most Recent Events

    • 01 Jul 2014 New trial record
    • 15 Jun 2014 Results presented at the 19th Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top